Loading
companiesCompany
NBE-Therapeutics
NBE-Therapeutics, founded in Basel in 2012 and owned by Boehringer Ingelheim since 2020, builds antibody-drug conjugates that pair its own conjugation chemistry with a PNU-derived anthracycline payload, designed to kill tumour cells directly and to trigger a lasting immune response against the tumour. Its candidates are still moving towards the clinic.
Overview
NBE-Therapeutics AG, founded in Basel in 2012, developed a next-generation antibody-drug conjugate platform for solid tumours combining its own conjugation technology, a PNU-derived anthracycline payload and antibody discovery capabilities. Its immune-stimulating ADC (iADC) concept aims for a long-lasting immuno-oncology effect in addition to direct cytotoxicity, with a pipeline of ADC candidates at various stages of development moving towards the clinic. The company became a wholly owned subsidiary of Boehringer Ingelheim in 2020 and in April 2025 opened a new ADC research and development centre in Basel that serves as a hub for Boehringer's ADC work.
Headquarters
Basel, CH
Funding
All startupsAcquiredAcquired by Boehringer Ingelheim
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Company states it became part of Boehringer Ingelheim in 2020; deal value not stated on the fetched page | 2020 | undisclosed | nbe-therapeutics.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Acquired
Website
Founded
2012
Notes
top- Boehringer Ingelheim's own acquisition release (reported elsewhere as up to EUR 1.18 billion, December 2020) is rendered client-side and returned no text to my fetches, so the deal value is omitted. Lead programme target (reported elsewhere as ROR1 for NBE-002) not stated on fetched pages.
Similar pages
- CompanyTallac Therapeutics
Shares Immune-stimulating antibody conjugate (ISAC), Antibody-drug conjugate (ADC).
- CompanyMersana Therapeutics
Shares Immune-stimulating antibody conjugate (ISAC), Antibody-drug conjugate (ADC).
- PathwaycGAS-STING innate sensing
Shares Immune-stimulating antibody conjugate (ISAC), Antibody-drug conjugate (ADC).
- RoadmapADC roadmap: from Mylotarg to bispecific and dual-payload ADCs
Shares Immune-stimulating antibody conjugate (ISAC), Antibody-drug conjugate (ADC).